The heterogeneity of Alzheimer’s disease (AD) goes beyond pathologies of tau and amyloid-beta (a-beta). It encompasses varying protein domains to be measured, different diagnostic technologies to measure them, and must take account of the evolving nature of the disease. This makes the task of developing biomarkers of disease progression more difficult than in other diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?